Community Translations

PD-L1-targeting drug atezolizumab nabs approval for NSCLC


The approval by the US Food and Drug Administration of the immune checkpoint inhibitor atezolizumab for the treatment of metastatic non–small cell lung cancer marked the second approved indication for the drug in a single year. Atezolizumab, which targets the programmed cell death protein-ligand 1, has a unique mechanism of action compared with other approved immune checkpoint inhibitors and had been previously approved for the treatment of patients with advanced urothelial carcinoma.

Click on the PDF icon at the top of this introduction to read the full article.

Next Article:

   Comments ()

Recommended for You

News & Commentary

Quizzes from MD-IQ

Research Summaries from ClinicalEdge